Wall Street brokerages forecast that CymaBay Therapeutics Inc (NASDAQ:CBAY) will post earnings of ($0.34) per share for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for CymaBay Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.38) and the highest estimate coming in at ($0.30). CymaBay Therapeutics reported earnings of ($0.32) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 6.3%. The firm is expected to report its next earnings results on Tuesday, May 14th.

On average, analysts expect that CymaBay Therapeutics will report full-year earnings of ($1.36) per share for the current year, with EPS estimates ranging from ($1.75) to ($1.13). For the next year, analysts anticipate that the company will post earnings of ($1.48) per share, with EPS estimates ranging from ($2.10) to ($0.70). Zacks’ earnings per share calculations are a mean average based on a survey of research firms that cover CymaBay Therapeutics.

Several research analysts have commented on the stock. Roth Capital restated a “buy” rating on shares of CymaBay Therapeutics in a research report on Tuesday, February 19th. BidaskClub downgraded CymaBay Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, April 11th. Zacks Investment Research downgraded CymaBay Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, January 21st. ValuEngine raised CymaBay Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Monday, April 1st. Finally, Leerink Swann began coverage on CymaBay Therapeutics in a research note on Friday, February 22nd. They issued an “outperform” rating and a $22.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. CymaBay Therapeutics presently has an average rating of “Buy” and an average target price of $19.38.

CBAY traded up $0.22 on Thursday, hitting $12.94. 326,872 shares of the company’s stock were exchanged, compared to its average volume of 704,548. The firm has a market cap of $762.41 million, a price-to-earnings ratio of -10.27 and a beta of 1.84. CymaBay Therapeutics has a twelve month low of $6.31 and a twelve month high of $15.00.

In other news, Director Carl Goldfischer sold 11,675 shares of CymaBay Therapeutics stock in a transaction that occurred on Thursday, February 7th. The stock was sold at an average price of $9.02, for a total value of $105,308.50. Following the completion of the transaction, the director now owns 2,335 shares in the company, valued at approximately $21,061.70. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 4.50% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Meeder Asset Management Inc. raised its holdings in CymaBay Therapeutics by 307.3% in the 1st quarter. Meeder Asset Management Inc. now owns 2,839 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 2,142 shares during the period. PNC Financial Services Group Inc. grew its position in shares of CymaBay Therapeutics by 23.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 13,120 shares of the biopharmaceutical company’s stock valued at $104,000 after purchasing an additional 2,460 shares in the last quarter. Bank of America Corp DE grew its position in shares of CymaBay Therapeutics by 1.5% in the fourth quarter. Bank of America Corp DE now owns 164,192 shares of the biopharmaceutical company’s stock valued at $1,291,000 after purchasing an additional 2,478 shares in the last quarter. Citigroup Inc. grew its position in shares of CymaBay Therapeutics by 17.7% in the fourth quarter. Citigroup Inc. now owns 19,966 shares of the biopharmaceutical company’s stock valued at $157,000 after purchasing an additional 3,000 shares in the last quarter. Finally, Raymond James & Associates grew its position in shares of CymaBay Therapeutics by 7.7% in the fourth quarter. Raymond James & Associates now owns 82,205 shares of the biopharmaceutical company’s stock valued at $647,000 after purchasing an additional 5,899 shares in the last quarter. 97.97% of the stock is owned by institutional investors and hedge funds.

CymaBay Therapeutics Company Profile

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.

Further Reading: Fiduciary

Get a free copy of the Zacks research report on CymaBay Therapeutics (CBAY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.